

16 January 2026

## Osteopore strikes exclusive collaboration with Majeton to access the Chinese market

### Highlights

- Osteopore strikes exclusive distribution agreement valued above RMB 12m with Majeton Pte Ltd (Majeton) to access the Chinese market, primarily in dental, orthodontic, and maxillofacial surgery with potential to enter other fields/indications.
- Majeton shall work with its parent company, Essex Bio-Technology Limited, listed on the Hong Kong Stock Exchange (01061.HK), and members of its group of companies for market access in China, Hong Kong, and Macau.
- This deal aligns with Osteopore's strategy of partnering with established players to accelerate commercialisation.

Australian-Singaporean regenerative medicine company **Osteopore Limited (ASX: OSX; Osteopore or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – is pleased to announce that it has entered into definitive agreements to commercialise its innovative dental, orthodontic, and maxillofacial products in China, Hong Kong, and Macau. This strategic initiative represents a significant milestone in the Company's expansion efforts within the Asia-Pacific region.

The agreement, valued above RMB 12m, includes upfront and milestone payments with further add-ons through purchase and supply of products. This structure reflects confidence in the market potential of Osteopore's products and our commitment to delivering high-quality solutions to dental, orthodontic, and maxillofacial professionals and patients.



Majeton is a sales, marketing, and distribution company of therapeutics, medical devices, and nutraceuticals for the region of South East Asia. The company embraces innovation to provide a portfolio of first-in-class and best-in-class products with the aim to deliver solutions to commercial and clinical unmet needs, covering a wide range of therapeutic areas.

Its parent company, Essex Bio-Technology Limited (**EssexBio**), is a Hong Kong-listed (01061.HK) bio-pharmaceutical company known for its expertise in developing, manufacturing, and commercialising genetically engineered therapeutic fibroblast growth factors (FGF). The company reported a 2024 turnover of HK\$1,669.8 million, and a profit increase of 11.6% to HK\$307 million. EssexBio's products are available in over 13,500 hospitals, supported by 43 regional sales offices. Recognised for its innovation and sustainable performance, EssexBio has been included in Forbes Asia's Best Under A Billion list 3 times, most recently in 2024<sup>1</sup>. This track record underscores their commitment to advancing healthcare through cutting-edge biopharmaceutical solutions.

**Key terms of the deal:**

- Multi-year exclusive commercial arrangement for China, Hong Kong, and Macau;
- Osteopore to receive upfront and milestone payments subject to meeting sales and regulatory milestones.

This partnership aligns with Osteopore's approach of working with established players<sup>2</sup> to accelerate commercialisation and meaningfully contribute to creating wider and positive impact on patient outcomes and healthcare ecosystem benefits.

Osteopore's products are clinically reported to achieve superior outcomes particularly in vertical bone augmentation and have received positive feedback from the community. The Chinese dental bone graft substitute and membrane market was valued at USD 212m in 2023, and expected to

---

<sup>1</sup> <https://www.forbes.com/lists/asia200/>

<sup>2</sup> ASX announcement "Osteopore strikes Exclusive Distribution with Zimmer Biomet", 16 July 2024.  
ASX announcement "Osteopore inks DKSH deal to sell ortho products in Singapore", 6 November 2025.



grow at a CAGR of 14% to reach USD 530m in 2030<sup>3</sup>. Osteopore's products are commercially relevant in both the dental bone graft substitute and membrane markets.

**Commenting on this exciting partnership, Osteopore CEO, Dr. Lim Yujing, said:**

"We are excited about the opportunities this partnership presents and look forward to collaborating closely with our partners to achieve our shared goals. Our team remains dedicated to innovation and excellence, and we are confident that this expansion will further solidify our position as a leader in the regenerative medicine industry."

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

**Lim Yujing**

Chief Executive Officer  
Osteopore Limited  
E: [lim\\_yujing@osteopore.com](mailto:lim_yujing@osteopore.com)

**Mark Leong**

Executive Chairman  
Osteopore Limited  
E: [mark\\_leong@osteopore.com](mailto:mark_leong@osteopore.com)

**About Osteopore Limited**

Osteopore Limited is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

<sup>3</sup> <https://idataresearch.com/product/dental-bone-graft-substitutes-market-china/>



### **About Majeton**

Majeton (a wholly-owned subsidiary of Essex Bio-Technology Limited), is a sales, marketing, and distribution company of therapeutics, medical devices, and nutraceuticals for the region of South East Asia. The company embraces innovation to provide a portfolio of first-in-class and best-in-class products with the aim to deliver solutions to commercial and clinical unmet needs, covering a wide range of therapeutic areas.

### **About Essex Bio-Technology Limited**

Essex Bio-Technology is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wounds healing and diseases in Ophthalmology and Dermatology.

These products are marketed and sold through approximately 13,500 hospitals, supported by the company's 43 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, Essex Bio-Technology maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications.

### **Forward-Looking Statements**

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates, and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any

revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of the information, opinions, or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's directors, employees, advisors, or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement.

The forward-looking statements in this announcement reflect views held only as of the date of this announcement. This announcement is not an offer, invitation, or recommendation to subscribe for or purchase securities by the Company, nor does this announcement constitute investment or financial product advice (nor tax, accounting, or legal advice), and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.